Learn About Chronic T-Cell Leukemia (CTCL)

View Main Condition: Leukemia

What is the definition of Chronic T-Cell Leukemia (CTCL)?
Chronic T-cell leukemia is a type of chronic lymphocytic leukemia (CLL), or cancer of the blood and bone marrow that mainly affects adults. In chronic T-cell leukemia, there is an overproduction of T lymphocytes, which are white blood cells that fight infection. Chronic T-cell leukemia has four subtypes: 1) large granular lymphocytic leukemia (LGLL), which is slow-growing; 2) T-cell prolymphocytic leukemia (T-PLL), which is aggressive, or fast-growing; 3) adult T-cell leukemia/lymphoma (ATLL); and 4) Sezary syndrome, which is a type of T-cell lymphoma that only occurs on the skin.
Save information for later
Sign Up
What are the symptoms of Chronic T-Cell Leukemia (CTCL)?
Individuals with early chronic T-cell leukemia may not have any symptoms. Symptoms of intermediate and advanced stage chronic T-cell leukemia depend on the type and may include painless, enlarged lymph nodes; fatigue; fever; pain in the upper left region of the abdomen; enlarged spleen; easy bruising or bleeding; pinpoint, dark red spots under the skin (petechiae); rash; frequent urination and/or constipation; night sweats; weight loss; abdominal pain or fullness; and frequent infections.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Chronic T-Cell Leukemia (CTCL)?
Treatment for chronic T-cell leukemia depends on the type and stage. Early stage chronic T-cell leukemia may not need treatment and may involve watchful waiting. Treatments for intermediate and advanced stages chronic T-cell leukemia may include targeted therapy, chemotherapy, radiation therapy, immunotherapy, splenectomy, and bone marrow or peripheral stem cell transplant.
Who are the top Chronic T-Cell Leukemia (CTCL) Local Doctors?
Elite
Elite
 
 
 
 
Learn about our expert tiers
Learn more
Elite
What are the latest Chronic T-Cell Leukemia (CTCL) Clinical Trials?
Phase I Multicenter Study of Ruxolitinib and Duvelisib in Relapsed or Refractory T- or NK-Cell Lymphomas

Summary: This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Letermovir for Cytomegalovirus Prophylaxis in Patients With Hematological Malignancies Treated With Alemtuzumab

Summary: This phase II trial studies how well letermovir works for the prevention of cytomegalovirus reactivation in patients with hematological malignancies treated with alemtuzumab. Patients receiving treatment with alemtuzumab may experience cytomegalovirus reactivation. Letermovir may block cytomegalovirus replication and prevent infection.

What are the Latest Advances for Chronic T-Cell Leukemia (CTCL)?